Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Kalaris Therapeutics Inc KLRS

Healthcare Biotechnology
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other... see more

Current News (NDAQ:KLRS)

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

GlobeNewswire March 17, 2026

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

GlobeNewswire January 28, 2026

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

GlobeNewswire December 17, 2025

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

GlobeNewswire December 17, 2025

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Newsfile November 24, 2025

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire November 12, 2025

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

GlobeNewswire November 3, 2025

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

GlobeNewswire October 30, 2025

UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

GlobeNewswire September 15, 2025
View More News ››

Opinion & Analysis (NDAQ:KLRS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:KLRS)

Using technical analysis for this stock.

It was a good buy for me at these low prices per share this morning,so good luck to all
coolfooldumbguy - September 3, 2025
View more Bullboard ››

ACL Construction Ltd.

ACL Construction Ltd.

A.C.L. Construction Ltd. operates as a construction company focusing on civil works, highway construction, utilities ...
View More »

Podcasts